Pembrolizumab berahyaluronidase alfa vs Retifanlimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline

Pembrolizumab berahyaluronidase alfa · Keytruda Qlex

Marketed by Merck & Co.

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT05722015 · Phase 3 · active, not recruiting

Patients were randomised to the subcutaneous or intravenous form with a prespecified non-inferiority margin, and both primary pharmacokinetic comparisons passed that margin. The primary endpoints are drug blood levels rather than tumour control or survival, and the study was open-label, so it shows comparable exposure but does not by itself show clinical benefit.

Next expected readout: December 2029 · NCT07190248 (registry estimate)

Reported efficacy

Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose (Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4, 15, 29, and 42 postdose (cycle length = 42 days)); Cycle 3: Trough Serum Concentration (Ctrough) of Pembrolizumab at Steady State (Cycle 3: Arm 1: Day 1: Predose and Days 4, 10, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4 and 42 postdose (cycle length = 42 days)): Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose (Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4, 15, 29, and 42 postdose (cycle length = 42 days)): Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy 1633.24 μg·day/mL (Geometric Coefficient of Variation 40.41) | Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy 1437.58 μg·day/mL (Geometric Coefficient of Variation 26.23) (met)

Result source: NCT05722015

Retifanlimab

Marketed by Incyte

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT04205812 · Phase 3 · completed

Participants were randomly assigned and double-blinded to receive retifanlimab or placebo with standard chemotherapy, with 391 in the retifanlimab group and 192 in the control group. The hard clinical primary endpoint of overall survival was met, favoring retifanlimab (hazard ratio 0.75; p=0.0042).

Next expected readout: December 2027 · NCT07219576 (registry estimate)

Reported efficacy

Overall Survival (up to 39.1 months): Overall Survival (up to 39.1 months): Retifanlimab + Chemotherapy 18.1 months (95% CI 16.2 to 21) vs Placebo + Chemotherapy 13.4 months (95% CI 11 to 16.7) (met)

Result source: NCT04205812

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointPembrolizumab berahyaluronidase alfaRetifanlimab
PFS, median—Trial running · NCT057220157.7 vs 5.5+2.2 vs placebon 391NCT04205812
OS, median—Trial running · NCT0572201518.1 vs 13.4+4.7 vs placebon 391NCT04205812
ORR64.3% vs 18.2%vs Pembrolizumabn 28NCT0621275251.7% vs 38.5%+13.2 vs placebon 391NCT04205812
Duration of response, median—Trial running · NCT0572201512.7 vs 6.1+6.6 vs placebon 202NCT04205812

PFS, median

Pembrolizumab berahyaluronidase alfa
—Trial running · NCT05722015
Retifanlimab
7.7 vs 5.5+2.2 vs placebon 391NCT04205812

OS, median

Pembrolizumab berahyaluronidase alfa
—Trial running · NCT05722015
Retifanlimab
18.1 vs 13.4+4.7 vs placebon 391NCT04205812

ORR

Pembrolizumab berahyaluronidase alfa
64.3% vs 18.2%vs Pembrolizumabn 28NCT06212752
Retifanlimab
51.7% vs 38.5%+13.2 vs placebon 391NCT04205812

Duration of response, median

Pembrolizumab berahyaluronidase alfa
—Trial running · NCT05722015
Retifanlimab
12.7 vs 6.1+6.6 vs placebon 202NCT04205812
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Pembrolizumab berahyaluronidase alfa: 2 of 4 rows · Retifanlimab: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricPembrolizumab berahyaluronidase alfaRetifanlimab
Dropout rate
n/a: no completion milestonea
NCT05722015 · Phase 3 · combination
show 1 more result
n/a: no completion milestone
NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
100%Retifanlimab + Chemotherapy
NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 1 more result
—Retifanlimab Monotherapy
NCT04205812 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Discontinued due to AEs
—a
NCT05722015 · Phase 3 · combination
show 1 more result
—
NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—Retifanlimab + Chemotherapy
NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 1 more result
—Retifanlimab Monotherapy
NCT04205812 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Serious AEs
39%a
NCT05722015 · Phase 3 · combination
show 1 more result
42.9%
NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
40.6%Retifanlimab + Chemotherapy
NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 1 more result
20.3%Retifanlimab Monotherapy
NCT04205812 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Most frequent reported AEs
a
anaemia 58.2%
neutropenia 41.8%
leukopenia 29.5%
NCT05722015 · Phase 3 · combination
show 1 more result
neutropenia 46.4%
anaemia 42.9%
constipation 39.3%
NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
anaemia 60.4% (placebo 56.8%)
decreased appetite 22.6% (placebo 13.2%)
neutrophil count decreased 21.6% (placebo 17.4%)
NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 1 more result
aspartate aminotransferase increased 23.7% (placebo 22.1%)
anaemia 22% (placebo 56.8%)
alanine aminotransferase increased 15.3% (placebo 23.7%)
NCT04205812 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Retifanlimab

Overall Survival 18.1 vs 13.4 placebo months
time to event · months
NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
PFS 7.7 vs 5.5 placebo months
time to event · months
NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Duration of Response 12.7 vs 6.1 placebo months
time to event · months
NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Pembrolizumab berahyaluronidase alfa's landscape · Retifanlimab's landscape